Introduction: Autoantibodies against the M-type phospholipase A2 receptor (PLA2R) are important markers in the diagnosis and monitoring of primary membranous nephropathy (pMN). For the detection of anti-PLA2R autoantibodies, a standardized recombinant cell-based indirect immunofluorescence assay (RC-IFA) and enzyme-linked immunosorbent assay (ELISA) are widely used, the former providing higher sensitivity but lacking a finely graduated quantification of antibody titers. In this study, we evaluated the diagnostic performance characteristics of a novel standardized chemiluminescence immunoassay (ChLIA) by comparison with the established anti-PLA2R test systems.
A utoantibodies against M-type PLA2R have become a valuable biomarker to differentiate pMN from secondary disease forms (membranous nephropathy due to another underlying disease). 1 Moreover, sequential anti-PLA2R titers are used for monitoring disease activity, assessment of response to therapy, and prognosis. [2] [3] [4] In recent years, standardized assays for the detection of autoantibodies against PLA2R have been developed. 2, 3 The RC-IFA is a highly sensitive method with particular capability in detecting very low anti-PLA2R titers, but semiquantitative results make it less adequate for monitoring disease progression and therapeutic response. 5, 6 Moreover, the suitability of RC-IFA for routine testing is limited because of error-prone subjective interpretation, a long turnaround time, and the requirement of specialized equipment. A quantitative anti-PLA2R ELISA is widely used for diagnosis and follow-up of pMN. Although it has been shown to provide high correlation with RC-IFA at very high specificity, the ELISA lags slightly behind in sensitivity, particularly in cases of therapeutic or spontaneous remission. 6, 7 Fast access to test results is crucial in clinical practice because early diagnosis and immediate immunotherapy may be life-saving in autoimmune pathologies. Therefore, diagnostic laboratories are increasingly shifting to fully automated random-access systems with focus on bead-based chemiluminescence technology. 8 The objective of this study was to evaluate the performance characteristics of a novel standardized anti-PLA2R ChLIA, and to determine if this assay can close the sensitivity gap between ELISA and RC-IFA.
METHODS

Patients and Samples
The study included 155 serum samples from patients with pMN who were referred to the INSERM Unit UMR_S1155 at Tenon Hospital (Paris, France). The clinical diagnosis of pMN was supported by histopathology of kidney biopsy 4, 9 in the absence of associations suggestive of secondary MN. All sera were sampled at around the time of biopsy in nephrotic patients with active disease. Moreover, 154 disease control sera were collected from patients with other biopsy-proven glomerular diseases and systemic autoimmune disorders (Table 1) . Control samples were obtained from INSERM Unit UMR_S1155 (Paris, France) and the Department of Rheumatology, Karolinska University Hospital (Stockholm, Sweden). Individual and ethical approval was not mandatory, as patient data and samples were used anonymously.
Immunoassays
The anti-PLA2R ChLIA (EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany) is based on magnetic beads coated with recombinant human PLA2R1 that was expressed in human embryonic kidney cells and purified as described previously. 6 The assay was performed fully automatically on a randomaccess analyzer (EUROIMMUN). All assay reagents were contained in a reagent cartridge, including PLA2R-coated beads, acridinium ester-conjugated antihuman IgG secondary antibodies (tracer), sample buffer, and diluent. Within the device, sample buffer and beads were transferred into a cuvette and patient sample was added at a dilution of 1:40. After 10 minutes at 37 C, unbound antibodies were removed by repeated magnetic force-mediated sedimentation and washing of the beads. Acridinium ester-conjugated anti-human IgG was then added and allowed to bind to the immobilized antibodies for 10 minutes at 37 C. The beads were sedimented and washed to remove unbound conjugate, followed by the addition of alkaline hydrogen peroxide to trigger the emission of light. The luminescence output from this reaction, which is directly proportional to the amount of anti-PLA2R bound to the antigen-coated beads, was measured luminometrically in relative light units over 10 seconds. Using a predefined lot-specific master curve and integrating the results of 2 calibrators, the system generated a standard curve adapted to the device in use. Based on this standard curve, the results were automatically converted from relative light units into chemiluminescent units per milliliter (CU/ml). In accordance with the manufacturer's recommendations, results $10 CU/ml were considered as positive.
The anti-PLA2R ELISA and RC-IFA (both EURO-IMMUN) were performed and evaluated as described before using the manufacturer's cutoff values. 6 Statistics Data were evaluated statistically using GraphPad Prism (GraphPad Software Inc., La Jolla, CA). Confidence intervals (95% CI) were calculated according to the modified Wald method. To examine the discriminatory ability of the assays, receiver operating characteristics curve analysis was carried out. Cohen's kappa test was performed to analyze the agreement between portions, with kappa (k) values corresponding to almost perfect (0.81-1.00), substantial (0.61-0.80), moderate (0.41-0.60), fair (0.21-0.40), slight (0.01-0.20), and no (#0) agreement. Spearman's rank correlation test was used to determine the degree of correlation between assays. P values <0.05 were considered significant.
RESULTS
Diagnostic Performance Characteristics of
ChLIA, ELISA, and RC-IFA Clinical sensitivity and specificity were assessed in 155 patients with biopsy-proven pMN and 154 disease Table S1 ). Receiver operating characteristics curve analysis revealed high areas under the curve for ChLIA (0.899), ELISA (0.927), and RC-IFA (0.916), indicating similar discrimination between patients with pMN and disease controls. ChLIA and RC-IFA outperformed the ELISA in terms of the maximum sum of sensitivity and specificity and with regard to sensitivity at predefined specificities. The manufacturer's cutoff (10 CU/ml) of the novel ChLIA lies slightly above the optimal cutoff (9.1 CU/ml), ensuring a specificity >99% (Table 3 , Supplementary Figure S1 ).
Correlation Between ChLIA and ELISA High overall concordance was found between qualitative anti-PLA2R results obtained by ChLIA and ELISA, as reflected by an agreement of 94.5% (95% CI: 91.3%-96.6%) and a k-value of 0.885 (95% CI: 0.833-0.938). A total of 114 samples (all pMN) were positive and 178 (25 pMN, 153 controls) negative by both methods (Figure 2 ). Seventeen samples (16 pMN, 1 minimal change disease) yielded discrepant results, that is, all of them reacted positively by ChLIA, whereas ELISA reactivity was in the borderline range in 4 cases and negative in 13 cases. Spearman's rank correlation analysis revealed a significant correlation between both assays (r ¼ 0.978, 95% CI: 0.969-0.984, P < 0.001; Figure 3a ).
The analytical imprecision expressed as coefficients of variation for positive, and near cutoff samples were calculated as within-run coefficients of variation (2.1%-6.5%) and total coefficients of variation (5.0%-10.3%) ( Supplementary Table S2 ). These results were similar to repeatability and reproducibility of the ELISA. 6 Correlation Between ChLIA and RC-IFA The anti-PLA2R ChLIA and RC-IFA yielded concordant results in 99.4% (95% CI: 97.5%-100%) of cases, with a k-value of 0.987 (95% CI: 0.968-1.000), indicating almost perfect agreement. A total of 129 samples (all pMN) were positive and 178 (25 pMN, 153 controls) negative by both methods (Figure 2 ). There were only 2 samples (1 pMN, 1 minimal change disease) with divergent qualitative results, both showing low positive ChLIA reactivity, whereas RC-IFA was negative. The Spearman's rank coefficient indicated strong correlation between ChLIA results and RC-IFA titers (r ¼ 0.894, 95% CI: 0.856-0.923, P < 0.001; Figure 3b ).
DISCUSSION
The present study investigated the diagnostic performance of a novel anti-PLA2R ChLIA in comparison with the established ELISA and RC-IFA. The clinical sensitivity of the ChLIA exceeded that of ELISA and RC-IFA by 10.4% and 0.7%, respectively, at similar specificities (>99%). The anti-PLA2R-positive rates detected by ChLIA (83.9%), ELISA (73.5%), and RC-IFA (83.2%) were equal to or higher than the prevalence data determined among non-preselected patients with pMN by different methods, such as Western blot (53.0%-81.7%), 10, 11 RC-IFA (48.0-82.3%), 12, 13 ELISA (50.0-71.8%), 14, 15 addressable laser bead immunoassay (51.5-66.9%), 16, 17 luciferase immunoprecipitation systems assay (53.3%), 18 and time-resolved fluoroimmunoassay (71.0-89.7%). 19, 20 These variations may be due to differences in assay techniques (e.g., epitope exposure, cutoff values, detected Ig subclass) and cohort characteristics (e.g., ethnicity, immunosuppressive treatment). Recently, Burbelo et al. 18 reported a quantitative PLA2R-NanoLuc luciferase immunoprecipitation system assay that provides high diagnostic performance (receiver operating characteristics area under the curve ¼ 1.0) and is, just like the novel ChLIA, more sensitive in detecting anti-PLA2R seropositivity than the ELISA. In the respective pMN panels, luciferase immunoprecipitation system found 1 and ChLIA found 16 additional anti-PLA2Rpositive samples compared with ELISA.
Most published studies using the EUROIMMUN anti-PLA2R ELISA adopted the manufacturerrecommended cutoff (20 relative units [RU]/ml), resulting in specificities ranging between 89.7% and 100%. 7, 14, 16, [21] [22] [23] [24] However, some studies used customized thresholds to increase sensitivity, sometimes leading to adverse effects on specificity. 16, 21, 22, 24 In the present study, receiver operating characteristics analysis revealed an optimum cutoff value of 3.0 RU/ml (maximum sum sensitivity and specificity). Applying this cutoff, 17 additional pMN samples would have been positive by ELISA (sensitivity 84.5%), whereas specificity would fall from 100% to 96.8%, which we consider unacceptable. Bobart et al. 25 recommended for centers preferentially performing ELISA, that samples giving ELISA values in the range between $2 and #20 RU/ml should be confirmed by RC-IFA owing to higher assay sensitivity.
In conclusion, the novel ChLIA is superior to ELISA in detecting autoantibodies against PLA2R, indicating its capability to improve diagnosis and follow-up testing of pMN. Its performance characteristics hold the potential for overcoming the sensitivity gap that exists between the established ELISA and RC-IFA, without compromising specificity. Fully automated random-access processing allows for rapid turnaround times and the option to incorporate the ChLIA into testing lines, giving laboratories with different requirements a higher degree of flexibility in their routines.
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